July 2024: A new study, published on July 3, 2024, indicates patients taking semaglutide such as Wegovy may face an increased risk of serious eye injuries, including nonarteritic anterior ischemic optic neuropathy (NAION)
Medical experts emphasize that these changes are typically temporary and may relate to the body's adjustment to new eating patterns and weight loss occurring as an impact of the medications T-2 diabetes management
Currently, metformin is the most commonly used insulin sensitizer for treating PCOS
This approval offers adults with obesity or overweight a beneficial new treatment option to incorporate into a weight management program, said John Sharretts, M.D., deputy director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDAs Center for Drug Evaluation and Research
Ozempic patients are also suffering from pancreatitis, gastroparesis, and vision loss, and they are filing lawsuits because of it
Donnarumma E, Kohlhaas M, Vimont E, Kornobis E, Chaze T, Gianetto QG, et al